Loading stock data…
Foghorn Therapeutics Inc (FHTX)
$4.86+0.64 (+15.17%)
Market ClosedLast close Jun 29
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Foghorn Therapeutics Inc. in the Healthcare sector is trading at $4.86 with a market capitalization of $235M. Wall Street consensus targets $11.44 (9 analysts), implying a +135.5% move over the next 12 months. The stock is currently 30% below its 52-week high of $6.95, remaining 0.8% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +135.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $3.27M↓ | $9.25M↑ | $8.15M↑ | $7.56M↑ | $5.95M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$21.57M↓ | -$19.60M↓ | -$18.50M↑ | -$21.10M↑ | -$22.91M |
| Net Income | -$19.88M↑ | -$21.66M↓ | -$15.85M↑ | -$17.94M↑ | -$18.83M |
Peer Comparison
JNJUNHPFE
Fundamentals
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses i...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$234.86M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
98.58%
Volume
Today's trading volume
384,830
Recent News
The Foghorn Therapeutics Inc. (NASDAQ:FHTX) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Foghorn Therapeutics Inc. ( NASDAQ:FHTX ) shareholders are probably feeling a little disappointed, since its shares...
CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimates
Foghorn Therapeutics (FHTX) delivered earnings and revenue surprises of -3.57% and -64.62%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Top Estimates
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of +253.07% and +56.20%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Foghorn Therapeutics Inc. (FHTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Foghorn Therapeutics (FHTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.